For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.
Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Servier Pharmaceuticals.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.1
2525 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.
Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Servier Pharmaceuticals.
Disclosure information is available at the beginning of the video presentation.
129 Listeners
5 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
27 Listeners
10 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
324 Listeners
2 Listeners
10 Listeners
2 Listeners
493 Listeners
279 Listeners
252 Listeners
3,332 Listeners
111,785 Listeners
56,191 Listeners
87 Listeners
1,090 Listeners
16,838 Listeners
515 Listeners
16,013 Listeners
349 Listeners
426 Listeners